Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSChrysoeriol is a flavonoid that has been found in Capsicum and has diverse biological activities.1,2,3,4 It is active against the Gram-positive bacteria E. faecalis, B. subtilis, and S. aureus (MICs = 1, 1, and 0.25 µg/ml, respectively) and the Gram-negative bacteria P. aeruginosa, K. pneumoniae, and E. coli (MICs = 0.12, 0.25, and 0.06 µg/ml, respectively).1 Chrysoeriol (7.5, 15, and 30 µM) induces cell cycle arrest at the G1 phase and autophagy in A549 lung cancer cells.2 It reduces LPS-induced production of IL-6, IL-1β, and TNF-α in RAW 264.7 cells when used at a concentration of 20 µM.3 Chrysoeriol (20 mg/kg) reduces plasma glucose, total cholesterol, free fatty acid, and phospholipid levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).4
WARNING This product is not for human or veterinary use.
1. Quantification, antioxidant and antimicrobial activity of phenolics isolated from different extracts of Capsicum frutescens (pimenta malagueta). Molecules 19(4), 5434-5447 (2014).
2. In vitro and in vivo cytotoxic effects of chrysoeriol in human lung carcinoma are facilitated through activation of autophagy, sub-
3. Chrysoeriol ameliorates TPA-
4. Antidiabetic and antihyperlipidemic activity of chrysoeriol in diabetic rats, role of HMG CoA reductase, LCAT and LPL: In vivo and in silico approaches. J. Pharm. Res. 9(9), 597-605 (2015).